2μg (N: non-reducing condition, R: reducing condition).
Biotinylated GUCY2C/Guanylyl cyclase C His&Avi Tag Protein, Human
Biotinylated GUCY2C/Guanylyl cyclase C His&Avi Tag Protein, Human
Price:
Regular price
$395 USD
Regular price
Sale price
$395 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | GUC2C,STAR,Guanylyl cyclase C |
| Accession | P25092 |
| Amino Acid Sequence | Ser24-Gln430 with His&Avi Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 70-100kDa(Reducing) |
| Endotoxin | <0.1EU/μg |
| Conjugation | Biotin |
| Tag | Avi Tag, His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, 5% trehalose, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
1. Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC Jr, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 Apr 23;7(1):104. 2.Arshad N, Ballal S, Visweswariah SS. Site-specific N-linked glycosylation of receptor guanylyl cyclase C regulates ligand binding, ligand-mediated activation and interaction with vesicular integral membrane protein 36, VIP36. J Biol Chem. 2013 Feb 8;288(6):3907-17. 3.Romi H, Cohen I, Landau D, Alkrinawi S, Yerushalmi B, Hershkovitz R, Newman-Heiman N, Cutting GR, Ofir R, Sivan S, Birk OS. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C. Am J Hum Genet. 2012 May 4;90(5):893-9. |
Background
Guanylyl cyclase C (GUCY2C) is a single-pass transmembrane receptor enzyme preferentially expressed in the intestinal epithelium. Its structure comprises an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase-like–guanylyl cyclase catalytic domain. Upon binding of ligands such as guanylin/uroguanylin, it catalyzes the conversion of GTP to cGMP, thereby regulating intestinal fluid and electrolyte secretion, barrier function, and intestinal motility. Clinically, GUCY2C agonists such as linaclotide and plecanatide are used for constipation-predominant irritable bowel syndrome and chronic idiopathic constipation; gain-of-function mutations can cause congenital sodium diarrhea, and in colorectal cancer GUCY2C serves as a therapeutic target for CAR-T cells targeting metastatic lesions and other therapies.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of Biotinylated GUCY2C/Guanylyl cyclase C His&Avi Tag Protein, Human is more than 95% as determined by SEC-HPLC.
ELISA
Immobilized Biotinylated GUCY2C/Guanylyl cyclase C His&Avi Tag Protein,Human (Cat. No. UA011377) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate, can bind Anti-human GUCY2C Monoclonal Antibody (Indusatumab) (Cat. No. UA016061) with a linear range of 0.68-1.3 ng/mL.
Immobilized Anti-human GUCY2C Monoclonal Antibody (Indusatumab) (Cat. No. UA016061) at 1 μg/mL (100 μL/well) can bind Biotinylated GUCY2C/Guanylyl cyclase C His&Avi Tag Protein,Human (Cat. No. UA011377) with a linear range of 2-2.5 ng/mL .
